SCHEMBL6709396

SCHEMBL6709396

O=Cc1ccc2c(ccn2Cc2ccc(F)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.53
HDAC1 Q13547 3/20 0.53
HDAC2 Q92769 3/20 0.53
HDAC8 Q9BY41 3/20 0.53
HDAC6 Q9UBN7 3/20 0.53
NPC1 O15118 1/20 0.51
HSP90AA1 P07900 1/20 0.51
CYP2A6 P11509 1/20 0.49
HDAC10 Q969S8 2/20 0.48
HDAC4 P56524 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
APP P05067 3/20 0.48
MAOB P27338 1/20 0.47
EPHX2 P34913 3/20 0.46
PLG P00747 1/20 0.45
PLAU P00749 1/20 0.45
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31258068 0.87 NPC1 (0.52) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL32683840 0.86 CYP2A6 (0.47) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL31257977 0.86 HDAC8 (0.51) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL15447279 0.86 HDAC8 (0.51) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL14207388 0.85 NPC1 (0.67) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL31258071 0.83 NPC1 (0.49) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL220738 0.82 APP (0.54) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL28475232 0.82 CYP2A6 (0.49) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL219871 0.81 PLAU (0.56) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL31674269 0.80 APP (0.46) HDAC3HDAC1HDAC2HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
EP-2578573-A1 FUSED IMIDAZOLE DERIVATIVE TOA Eiyo Ltd. (JP) 2013-04-10 EP disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed
CN-102906074-A Fused imidazole derivative TOA EIYO LTD 2013-01-30 CN disclosed
US-20040067998-A1 Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition YANG JI CHEMICAL COMPANY LTD (KR) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A HDAC3 1893/4885HDAC1 1612/4885HDAC2 1084/4885
US-20040067998-A1 Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition IDO1, IDO2, TPH1 HDAC3 600/4885HDAC1 699/4885HDAC2 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.